Sugi Predict

Sugi Predict / Targets / CDK19

CDK19

Cyclin-dependent kinase 19 · Q9BWU1 · CDK19 on Sugi Atlas →

22,149 patent compounds predicted against CDK19, 14,492 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1006747 SCHEMBL1006747 0.44 9/20
SCHEMBL1096010 SCHEMBL1096010 0.42 7/20
SCHEMBL426655 SCHEMBL426655 1.00 6/20
SCHEMBL421613 SCHEMBL421613 0.77 5/20
SCHEMBL422546 SCHEMBL422546 0.71 5/20
SCHEMBL422916 SCHEMBL422916 0.69 5/20
SCHEMBL420315 SCHEMBL420315 0.67 5/20
SCHEMBL423436 SCHEMBL423436 0.67 5/20
SCHEMBL425875 SCHEMBL425875 0.65 5/20
Linifanib Linifanib (SCHEMBL93804) 1.00 4/20
SCHEMBL420207 SCHEMBL420207 0.79 4/20
SCHEMBL424914 SCHEMBL424914 0.78 4/20
SCHEMBL423390 SCHEMBL423390 0.77 4/20
SCHEMBL425633 SCHEMBL425633 0.76 4/20
SCHEMBL423713 SCHEMBL423713 0.76 4/20
SCHEMBL421603 SCHEMBL421603 0.74 4/20
SCHEMBL423081 SCHEMBL423081 0.69 4/20
SCHEMBL421664 SCHEMBL421664 0.69 4/20
SCHEMBL425284 SCHEMBL425284 0.64 4/20
SCHEMBL425755 SCHEMBL425755 0.62 4/20

Clinical trials — most relevant to CDK19 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt PHASE4COMPLETED
A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714) PHASE3COMPLETED
A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2) PHASE3COMPLETED
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) PHASE3RECRUITING
Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression PHASE2COMPLETED
Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC PHASE2ACTIVE_NOT_RECRUITING
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer PHASE2UNKNOWN
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6 PHASE2RECRUITING
A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia PHASE2COMPLETED
CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer PHASE2ACTIVE_NOT_RECRUITING
A Clinical Trial of TQB3909 Tablets in Patients With Breast Cancer PHASE1/PHASE2UNKNOWN
Abemaciclib With or Without Atezolizumab for mCRPC PHASE2COMPLETED
A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation PHASE2ACTIVE_NOT_RECRUITING
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer PHASE2COMPLETED
To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy PHASE2COMPLETED
Cyclin Dependent Kinase (CDK)4/6 Inhibitor, PD0332991 in Advanced Non-small Cell Lung Cancer NSCLC. PHASE2COMPLETED
A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer PHASE2COMPLETED
Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors PHASE1/PHASE2COMPLETED
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC) PHASE1/PHASE2RECRUITING
Histology-Independent Study of Palbociclib in Patients With Advanced Cancer PHASE2WITHDRAWN
BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors PHASE2WITHDRAWN
Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer PHASE2RECRUITING
AZD1775 for Advanced Solid Tumors PHASE1COMPLETED
Open Label Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms PHASE1COMPLETED
Study of PHA-848125AC in Adult Patients With Advanced/Metastatic Solid Tumors PHASE1COMPLETED
A Study of PRT2527 in Participants With Advanced Solid Tumors PHASE1COMPLETED
Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer PHASE1ACTIVE_NOT_RECRUITING
Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma PHASE1COMPLETED
Incidence of Venous Thromboembolism and Cardiovascular Events in Breast Cancer Patients Undergoing Cyclin-dependent Kinase 4/6 Inhibitors: The Breast Cancer Associated Vascular Events During Cyclin-dependent Kinase 4/6 Inhibitors Therapy (BRAVE-Cyclin) Study nanACTIVE_NOT_RECRUITING
Advanced Breast Cancer Study of CDK4/6 Inhibitor Combined With Endocrine Therapy Endocrine Therapy in HR+/HER2- Advanced Breast Cancer nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a CDK19 binder may also engage these)

ProteinNameSimilarity
Q8BWD8 — 1.000 Q8BWD8 →
Q8JH47 — 0.999 Q8JH47 →
Q8R3L8 — 0.994 Q8R3L8 →
Q6P3N6 — 0.993 Q6P3N6 →
CDK8 Cyclin-dependent kinase 8 0.992 landscape →
Q17IE8 — 0.960 Q17IE8 →
Q9VT57 — 0.952 Q9VT57 →
MAPKAPK2 MAP kinase-activated protein kinase 2 0.945 landscape →
O54949 — 0.944 O54949 →
DHX9 ATP-dependent RNA helicase A 0.940 landscape →
P49139 — 0.938 P49139 →
D3ZSZ3 — 0.938 D3ZSZ3 →
E1BMN8 — 0.938 E1BMN8 →
NLK Serine/threonine-protein kinase NLK 0.937 landscape →
Q5R874 — 0.937 Q5R874 →
STK39 STE20/SPS1-related proline-alanine-rich protein kinase 0.936 landscape →
P49138 — 0.936 P49138 →
O88506 — 0.935 O88506 →
E2QWQ2 — 0.933 E2QWQ2 →
Q9Z1W9 — 0.933 Q9Z1W9 →
A5PKA5 — 0.931 A5PKA5 →
CTNNB1 Catenin beta-1 0.931 landscape →
A2A432 — 0.931 A2A432 →
Q80T74 — 0.931 Q80T74 →
Q96CT2 — 0.931 Q96CT2 →
Q28141 — 0.930 Q28141 →
B6V8E6 — 0.930 B6V8E6 →
Q3UHD6 — 0.929 Q3UHD6 →
O70133 — 0.929 O70133 →
Q3TIX9 — 0.928 Q3TIX9 →